Progesterone loading as a strategy for treating postpartum depression.
allopregnanolone
postpartum depression
progesterone
Journal
Human psychopharmacology
ISSN: 1099-1077
Titre abrégé: Hum Psychopharmacol
Pays: England
ID NLM: 8702539
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
24
07
2019
revised:
16
12
2019
accepted:
12
03
2020
pubmed:
7
4
2020
medline:
30
1
2021
entrez:
7
4
2020
Statut:
ppublish
Résumé
Postpartum depression (PPD) is a severe disorder that adversely impacts both mothers and infants. It is associated with significant morbidity and mortality and reported prevalence is 11.5% (Ko, Rockhill, Tong, Morrow, & Farr. (2017). MMWR Morbidity and Mortality Weekly Report, 66(6), 153-158). Although PPD's fundamental pathophysiology remains to be fully illuminated, the influence of changes in perinatal hormones such as allopregnanolone (an endogenous progesterone metabolite) are most promising avenues of research. Conventional treatments for PPD are aligned with treatment strategies for depressive disorders. Brexanolone is a small molecule, neuroactive steroid GABA
Substances chimiques
Progesterone
4G7DS2Q64Y
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2731Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Aebi, S., Schnider, T. W., Los, G., Heath, D. D., Darrah, D., Kirmani, S., … Christen, R. D. (1999). A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemotherapy and Pharmacology, 44(3), 259-265. https://doi.org/10.1007/s002800050976
Ahokas, A., Aito, M., & Rimon, R. (2000). Positive treatment effect of estradiol in postpartum psychosis: A pilot study. The Journal of Clinical Psychiatry, 61(3), 166-169.
Andreen, L., Spigset, O., Andersson, A., Nyberg, S., & Backstrom, T. (2006). Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone. Maturitas, 54(3), 238-244. https://doi.org/10.1016/j.maturitas.2005.11.005
Baker, E. R., Best, R. G., Manfredi, R. L., Demers, L. M., & Wolf, G. C. (1995). Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. Journal of Assisted Reproduction and Genetics, 12(3), 205-209.
Bloch, M., Schmidt, P. J., Danaceau, M., Murphy, J., Nieman, L., & Rubinow, D. R. (2000). Effects of gonadal steroids in women with a history of postpartum depression. The American Journal of Psychiatry, 157(6), 924-930. https://doi.org/10.1176/appi.ajp.157.6.924
Casas, S., Garcia, S., Cabrera, R., Nanfaro, F., Escudero, C., & Yunes, R. (2011). Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats. Pharmacology, Biochemistry, and Behavior, 99(4), 614-618. https://doi.org/10.1016/j.pbb.2011.06.012
Christen, R. D., McClay, E. F., Plaxe, S. C., Yen, S. S., Kim, S., Kirmani, S., … Freddo, J. L. (1993). Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. Journal of Clinical Oncology, 11(12), 2417-2426. https://doi.org/10.1200/jco.1993.11.12.2417
Dennerstein, L., Spencer-Gardner, C., Gotts, G., Brown, J. B., Smith, M. A., & Burrows, G. D. (1985). Progesterone and the premenstrual syndrome: A double blind crossover trial. British Medical Journal (Clinical Research Ed.), 290(6482), 1617-1621.
Frye, C. A., & Walf, A. A. (2009). Progesterone reduces depression-like behavior in a murine model of Alzheimer's disease. Age (Dordrecht, Netherlands), 31(2), 143-153. https://doi.org/10.1007/s11357-009-9091-6
Huang, C. C., Wei, I. H., Chou, Y. H., & Su, T. P. (2008). Effect of age, gender, menopausal status, and ovarian hormonal level on rTMS in treatment-resistant depression. Psychoneuroendocrinology, 33(6), 821-831. https://doi.org/10.1016/j.psyneuen.2008.03.006
Kanes, S. J., Colquhoun, H., Doherty, J., Raines, S., Hoffmann, E., Rubinow, D. R., & Meltzer-Brody, S. (2017). Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Human Psychopharmacology, 32(2), e2576. https://doi.org/10.1002/hup.2576
Klatzkin, R. R., Morrow, A. L., Light, K. C., Pedersen, C. A., & Girdler, S. S. (2006). Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone. Psychoneuroendocrinology, 31(10), 1208-1219. https://doi.org/10.1016/j.psyneuen.2006.09.002
Ko, J. Y., Rockhill, K. M., Tong, V. T., Morrow, B., & Farr, S. L. (2017). Trends in postpartum depressive symptoms-27 states, 2004, 2008, and 2012. MMWR Morbidity and Mortality Weekly Report, 66(6), 153-158.
Landgren, B. M., Jonsson, B., & Cekan, S. Z. (1995). The effect of small doses of progesterone released from two types of vaginal rings on ovarian activity and bleeding patterns during the first postpartum year. Contraception, 51(4), 255-260. https://doi.org/10.1016/0010-7824(95)00042-9
Li, Y., Raaby, K. F., Sanchez, C., & Gulinello, M. (2013). Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behavioural Brain Research, 256, 520-528. https://doi.org/10.1016/j.bbr.2013.09.002
Lieberman, A., & Curtis, L. (2017). In Defense of progesterone: A review of the literature. Alternative Therapies in Health and Medicine, 23(6), 24-32.
Luisi, S., Petraglia, F., Benedetto, C., Nappi, R. E., Bernardi, F., Fadalti, M., … Genazzani, A. R. (2000). Serum allopregnanolone levels in pregnant women: Changes during pregnancy, at delivery, and in hypertensive patients. The Journal of Clinical Endocrinology and Metabolism, 85(7), 2429-2433. https://doi.org/10.1210/jcem.85.7.6675
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., … Kanes, S. (2018). Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet, 392(10152), 1058-1070. https://doi.org/10.1016/s0140-6736(18)31551-4
Pharmac. (2019). ScheduleOnline.php?osq=Progesterone. Retrieved from https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?osq=Progesterone
Phillips, S. J., Tepper, N. K., Kapp, N., Nanda, K., Temmerman, M., & Curtis, K. M. (2016). Progestogen-only contraceptive use among breastfeeding women: A systematic review. Contraception, 94(3), 226-252. https://doi.org/10.1016/j.contraception.2015.09.010
Post, W. (2019). first-drug-specifically-postpartum-depression-is-approved. Retrieved from https://www.washingtonpost.com/health/2019/03/19/first-drug-specifically-postpartum-depression-is-approved/?noredirect=on&utm_term=.64a2bdeabbae
RamaRao, S., Clark, H., Merkatz, R., Sussman, H., & Sitruk-Ware, R. (2013). Progesterone vaginal ring: Introducing a contraceptive to meet the needs of breastfeeding women. Contraception, 88(5), 591-598. https://doi.org/10.1016/j.contraception.2013.05.004
Roberts, T. A., & Hansen, S. (2017). Association of Hormonal Contraception with depression in the postpartum period. Contraception, 96(6), 446-452. https://doi.org/10.1016/j.contraception.2017.08.010
Ti, A., & Curtis, K. M. (2019). Postpartum hormonal contraception use and incidence of postpartum depression: A systematic review. The European Journal of Contraception & Reproductive Health Care, 24(2), 109-116. https://doi.org/10.1080/13625187.2019.1569610
Trauger, J. W., Jiang, A., Stearns, B. A., & LoGrasso, P. V. (2002). Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry, 41(45), 13451-13459.